Last Updated: September 28, 2026

Details for New Drug Application (NDA): 017106


✉ Email this page to a colleague

« Back to Dashboard


NDA 017106 describes ATROPEN, which is a drug marketed by MMT and is included in one NDA. It is available from one supplier. Additional details are available on the ATROPEN profile page.

The generic ingredient in ATROPEN is atropine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine profile page.
Summary for 017106
Tradename:ATROPEN
Applicant:Mmt
Ingredient:atropine
Patents:0
Pharmacology for NDA: 017106
Mechanism of ActionCholinergic Antagonists
Cholinergic Muscarinic Antagonists
Medical Subject Heading (MeSH) Categories for 017106
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Bronchodilator Agents
Muscarinic Antagonists
Mydriatics
Parasympatholytics
Suppliers and Packaging for NDA: 017106
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106 NDA Meridian Medical Technologies LLC 11704-101 11704-101-01 .7 mL in 1 SYRINGE, PLASTIC (11704-101-01)
ATROPEN atropine SOLUTION;INTRAMUSCULAR 017106 NDA Meridian Medical Technologies LLC 11704-104 11704-104-01 .7 mL in 1 SYRINGE, PLASTIC (11704-104-01)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAMUSCULARStrengthEQ 2MG SULFATE/0.7ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAMUSCULARStrengthEQ 1MG SULFATE/0.7ML
Approval Date:Jun 19, 2003TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAMUSCULARStrengthEQ 0.5MG SULFATE/0.7ML
Approval Date:Jun 19, 2003TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links